Children with ETV6::RUNX1 or high-hyperdiploid B-cell acute lymphoblastic leukemia (B-ALL) have favorable outcomes. The St. Jude (SJ) classification considers these patients low risk, regardless of their National Cancer Institute (NCI) risk classification, except when there is slow minimal residual disease (MRD) response or central nervous system/testicular involvement.
View Article and Find Full Text PDFInfection is a major cause of treatment-related morbidity and mortality in pediatric acute lymphoblastic leukemia (ALL). Most children with ALL who develop life-threatening bacterial infections do so during induction therapy. We describe a rare case of ALL presenting simultaneously with Streptococcus agalactiae group B Streptococcus bacteremia and meningitis in a 3-year-old girl.
View Article and Find Full Text PDFPurpose: The Stanford V chemotherapy regimen has been used to treat Hodgkin lymphoma (HL) patients since 2002 with excellent cure rates; however, mechlorethamine is no longer available. Bendamustine, a drug structurally similar to alkylating agents and nitrogen mustard, is being substituted for mechlorethamine in combination therapy in a frontline trial for low- and intermediate-risk pediatric HL patients, forming a new backbone of BEABOVP (bendamustine, etoposide, doxorubicin, bleomycin, vincristine, vinblastine, and prednisone). This study evaluated the pharmacokinetics and tolerability of a 180 mg/m dose of bendamustine every 28 days to determine factors that may explain this variability.
View Article and Find Full Text PDFPast studies of Ultraviolet-C (UV-C) radiation as a marine antifoulant have focused on repeated doses. However, single or very low frequency exposures of UV-C could create more plausible applications for certain marine structures. The objective of the study reported here was to apply a single treatment of UV-C radiation to an early stage marine biofouling community to observe subsequent effects on biofouling development.
View Article and Find Full Text PDF